Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC,
NASDAQ:ONCY) is pleased to announce that it has completed patient enrolment in
its Phase I U.S. clinical trial investigating the systemic delivery of
REOLYSIN(R) to treat patients with advanced cancers. A total of 18 patients
were treated in the Phase I trial with REOLYSIN(R) at escalating dosages of
1x10(8), 3x10(8), 1x10(9), 3x10(9), 1x10(10) or 3x10(10) TCID(50). A maximum
tolerated dose (MTD) was not reached and the treatment appears to have been
well tolerated by the patients.
